FutureSearch Trials of Neurology Receives Clinical Research Site Award from Sponsor
Dr. John Hudson and the FutureSearch Trials of Neurology team received the following award announcement from a sponsor:
“To recognize the value of clinical research sites as a partner in the clinical research process, (sponsor) is presenting a Clinical Research Site Award to selected sites. It is my great pleasure to inform you that FutureSearch Trials of Neurology has been selected as a recipient of a Clinical Research Site Award for your participation in the (sponsor) Migraine Study. This award recognizes your site for your accomplishments and contributions.
Your (sponsor) team members had the following comments in nominating you for this recognition:
• Efficient Study Start-up demonstrated by timely review of contracts and budgets, timely provision of essential documents and IRB/IEC submissions.
○ The site implemented extremely efficient start up process enabling timely site activation.
• Enrollment rates demonstrated by meeting or exceeding the agreed upon number of evaluable patients on schedule.
○ The site exceeded their target enrollment goal for the study.
• Protocol Adherence demonstrated by minimal number of protocol deviation, accurate drug accountability, adherence to eligibility criteria and visit schedule.
○ The site performed high quality screening assessments leading to a low screen failure rate.”
• Efficient Study Start-up demonstrated by timely review of contracts and budgets, timely provision of essential documents and IRB/IEC submissions.
○ The site implemented extremely efficient start up process enabling timely site activation.
• Enrollment rates demonstrated by meeting or exceeding the agreed upon number of evaluable patients on schedule.
○ The site exceeded their target enrollment goal for the study.
• Protocol Adherence demonstrated by minimal number of protocol deviation, accurate drug accountability, adherence to eligibility criteria and visit schedule.
○ The site performed high quality screening assessments leading to a low screen failure rate.”
